Results 211 to 220 of about 5,542 (243)
Some of the next articles are maybe not open access.
Naunyn-Schmiedeberg's Archives of Pharmacology
Information on biosimilars was rarely disseminated on the Pharmaceuticals and Medical Devices Agency (PMDA) website of the Japanese Regulatory Agency until the fiscal year (FY) 2022. Therefore, the PMDA website for biosimilars was created in FY 2023.
Ryosuke Kuribayashi +3 more
openaire +2 more sources
Information on biosimilars was rarely disseminated on the Pharmaceuticals and Medical Devices Agency (PMDA) website of the Japanese Regulatory Agency until the fiscal year (FY) 2022. Therefore, the PMDA website for biosimilars was created in FY 2023.
Ryosuke Kuribayashi +3 more
openaire +2 more sources
Biosimilars Pharmaceutical Market in India: Current Status, Challenges and Future Perspective
Bioscience Biotechnology Research Communications, 2021openaire +1 more source
P & T : a peer-reviewed journal for formulary management, 2014
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source